PD-1+ Tim-3+ and PD-1+ Tim-3− exhausted T cells significantly increase in mice with de novo mature B cell neoplasms. Our mouse model with conditional Utx loss and BrafV600E expression only in mature B cells develops mature B cell neoplasms de novo with time. Sick mice were euthanized, and BM, the spleen, and LN cells were harvested and analyzed using flow cytometry. Cre-negative mice were also analyzed as controls. a Representative flow plots of PD-1 and Tim-3 expression on CD8+ T cells in BM, the spleen, and LNs of control or sick mice. b, c The proportion of PD-1+ Tim-3+ T cells (b) and PD-1+ Tim-3− T cells (c) in BM, the spleen, and LNs of control or sick mice, expressed as a percentage of total CD8+ T cells (BM: control n = 26, mature B cell neoplasms n = 17 [plasma cell neoplasms 7, B cell lymphoma 8, LPD 2]; spleen: control n = 28, mature B cell neoplasms n = 20 [plasma cell neoplasms 10, B cell lymphoma 8, LPD 2]; LN: control n = 18, mature B cell neoplasms n = 17 [plasma cell neoplasms 8, B cell lymphoma 7, LPD 2]). d, e The proportion of PD-1+ Tim-3+ T cells (d) and PD-1+ Tim-3− T cells (e) to CD8+ T cells in invasion-negative or -positive organs (BM: invasion-negative n = 6 [plasma cell neoplasms 2, B cell lymphoma 4], -positive n = 11 [plasma cell neoplasms 5, B cell lymphoma 4, LPD 2]; spleen: invasion-negative n = 4 [plasma cell neoplasms 2, B cell lymphoma 2], -positive n = 16 [plasma cell neoplasms 8, B cell lymphoma 6, LPD 2]; LN: invasion-negative n = 4 [plasma cell neoplasms 1, B cell lymphoma 2, LPD 1], -positive n = 13 [plasma cell neoplasms 7, B cell lymphoma 5, LPD 1]). The significance of differences was assessed by an unpaired t-test. Horizontal bars indicate means, and error bars represent SD